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Abstract MLN 50 was previously identified in a cDNA library 
of breast cancer metastasis. In this study, we show that MLN 50, 
which is expressed at a basal level in normal tissues, is overex- 
pressed in 8% of human breast carcinomas most often together 
with c-erbB-2. MLN 50 cDNA encodes a putative protein of 261 
residues, named Lasp-1 (LIM and SH3 protein) since it contains 
- LIM motif and a domain of Src homology region 3 (SH3) at 
the amino- and the C-terminal parts of the protein, respectively. 
Thus, Lasp-1 defines a new LIM protein subfamily. 
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~. Introduction 
Breast cancer is one of the most common types of cancer 
.~ffecting women. Despite improvement in the early detection 
,f small tumors and in treatment, associated metastases remain 
he leading cause of mortality for breast cancer patients [1]. 
'vILN 50 (Lasp-l) cDNA was identified from a breast cancer- 
~lerived metastatic lymph node cDNA library by differential 
lybridization using malignant (metastatic lymph node) vs. non- 
nalignant (breast fibroadenoma and normal ymph node) tis- 
,ues. Chromosomal mapping showed that the Lasp-1 gene is 
ocalized on the q12-q21 region of the long arm of chromosome 
7. This region is known to be altered in 20-30% of breast 
• ancers, the most common modification being the amplification 
)f the proto-oncogene c- rbB-2 [24]. In breast cancer cell lines 
we found that overexpression f Lasp-1 RNA was correlated 
~ith amplification of the gene and to c-erbB-2 amplification/ 
)verexpression, suggesting that Lasp-1 and c-erbB-2 belong to 
:he same amplicon [5]. The aim of this study was to determine 
1he frequency of Lasp- 1 overexpression in human breast cancer 
md to characterize the structure of the putative protein en- 
:oded by this gene. 
2. Materials and methods 
?. 1. Tissues 
Surgical specimens obtained from the H6pitaux Universitaires de 
~,trasbourg were frozen in liquid nitrogen for RNA extraction. 
2.2. RNA preparation and analysis 
Surgical specimens were homogenized in guanidinium isothiocyanate 
[ysis buffer and RNAs purified by centrifugation through cesium chlo- 
*Corresponding author. Fax: (33) (88) 65 32 01. 
ride cushions [6]. RNAs were fractionated by electrophoresis on 1% 
agarose, 2.2 M formaldehyde g ls [7], transferred tonylon membrane 
(Hybond N; Amersham, Arlington Heights, IL) and immobilized by 
baking for 2 h at 80 °C. 
2.3. Probe preparation and hybridization 
The Lasp-I probe corresponded to a 1.0-kb BamHI fragment re- 
leased from MLN 50 cDNA (Accession X82456) [5] subcloned into 
pBluescript (Stratagene, La Jolla, CA). The c-erbB-2-specific probe was 
a EcoRI internal fragment of MLN 19 cDNA [5]. The RNA loading 
control probe 36B4 was an internal 0.7-kb Pstl fragment [8]. 
Northern blots were hybridized at 42°C in 50% formamide, 5 × SSC, 
0.4% ficoll, 0.4% polyvinylpyrrolidone, 20 mM sodium phosphate pH 
6.5, 0.5% SDS, 10% dextran sulfate and 100/lg/ml denatured salmon 
sperm DNA, for 3~48 hwith 32p-labeled probes [9] diluted to 0.5 1.10 6 
cpm/ml. Stringent washings were performed at 60°C in 0.1 x SSC and 
0,1% SDS. Blots were subjected to autoradiography at -80°C for 
24 h. 
2.4. Sequence analysis 
Sequence analysis was performed using the GCG sequence analysis 
package (Wisconsin package version 8.0, Genetics Computer Group, 
Madison, WI). The Lasp-1 cDNA sequence and its deduced putative 
protein sequence were used to search the complete combined GenBank/ 
EMBL database (Release 84/42) and the complete SwissProt database 
(Release 31) with BLAST [10] and FastA [11] programs, respectively. 
The LIM motif and other consensus sequences of Lasp-1 were further 
identified by the Motif program in the PROSITE dictionary (Release 
12). The sequence alignments were obtained automatically b using the 
program PileUp [12]. 
3. Results and discussion 
3. I. Lasp-1 is overexpressed in breast carcinomas 
To study Lasp-1 mRNA distribution, we carried out North- 
ern blot analysis using the cDNA probe (see Section 2). A single 
4.0-kb mRNA band was detected at a basal evel in all normal 
human tissues examined, including lymph node, skin, lung, 
stomach, colon and liver (data not shown), in non-malignant 
breast fibroadenomas (Fig. 1A, lanes 13-17) and in breast hy- 
perplasia (Fig, 1A, lane 18). High levels of Lasp-1 mRNA were 
found in 8% (5/61) of primary breast cancers (Fig. 1A, lane 8 
and data not shown) and in 40% (2/5) of metastatic lymph 
nodes derived from breast cancer (Fig. IA, lanes 1 and 2, and 
data not shown), c-erbB-2 hybridization of the same blots 
showed that Lasp-1 and c-erbB-2 were simultaneously overex- 
pressed in most human breast cancer tissues (Fig. 1A, lanes 1, 
2 and 8). Nevertheless, ome malignant samples displayed c- 
erbB-2 overexpression independantly of Lasp-I overexpression 
(Fig. IA, lane 12). Thus, these results howed that Lasp-1 which 
is widely expressed at a basal level in normal tissues is over- 
expressed in some breast cancers and their derivative meta- 
static lymph nodes. It has been shown previously that, in 
breast cancer cell lines, overexpression f Lasp-1 is correlated 
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Fig. 1. Northern blot analysis of Lasp-1 mRNA expression i human 
breast issues. Total RNA (10 Bg) were loaded, transferred and hybrid- 
ized with 32p-labeled probes specific for c-erbB-2, Lasp-1 and to the 
RNA loading control 36B4. Approximative transcript sizes are indi- 
cated (right). RNA extracted from breast metastatic lymph nodes 
(MLN; lanes 1 and 2), carcinomas (lanes 3-12), fibroadenomas (lanes 
13 17) and hyperplasia (lane 18). 
to Lasp-1 gene amplification [5]. Moreover, Lasp-1 has been 
mapped to the human chromosome 17 close to the c-erbB-2 
oncogene [2,5]. Altogether, these results suggest that amplifica- 
tion of the q l l-q21 region of chromosome 17, one of the most 
common events occurring in human breast cancers and pre- 
sumed to target he e-erbB-2 gene [3,4], could lead to Lasp-1 
overexpression. 
3.2. Lasp-1 eDNA sequence 
The complete Lasp-1 cDNA sequence has been established 
from four independent cDNA clones. Both sense and antisense 
strands have been sequenced. The longest cDNA clone con- 
tained 3848 bp (Fig. 2A), a size consistent with that of the 
Lasp-1 transcript, suggesting that this clone should correspond 
to the full length cDNA. The first ATG codon (nucleotide 
position 76-78, Fig. 2A) had a favorable context for initiation 
of translation [13] and a classical AATAAA poly(A) addition 
signal sequence [14] was located 13 bp upstream of the poly(A) 
stretch (Fig. 2A). At the nucleotide l vel, sequence homologies 
were found with 22 expressed sequence tag (EST) [15]. Some 
of these sequences were redundant and they were mostly lo- 
cated at the 3' untranslated end of the molecule (Fig. 2B). These 
EST were identified from different human cDNA libraries es- 
tablished from normal tissues (prostate gland, liver and fetal 
spleen and brain) and cells (white blood and pancreatic islet 
cells). The presence of Lasp-1 transcripts in all these samples 
is in good agreement with our finding of an ubiquitous expres- 
sion of Lasp-1 mRNA (data not shown). 
3.3. Lasp-1 putative protein sequence 
The deduced Lasp-1 open reading frame encoded a 261 
amino acid protein (Fig. 2A), with a molecular weight of 30 
kDa and a pHi of 6.5. The putative protein showed several 
consensus sequences [16]: an amidation site (GGKR, residues 
203-206), several phosporylation sites characteristic ofcAMP- 
and cGMP-dependent protein kinases (RRDS, 143-146), ca- 
sein kinase II (SGGE, 134-137; SAAD, 214-217; SFQD, 222- 
225), proteine kinase C (TEK, 15-17; TCK, 34-36; SYR, 151- 
153) and tyrosine kinases (KGYEKKPY, 45-52; 
RDSQDGSSY, 144-152). Moreover, a LIM cysteine-rich do- 
main [17] was identified at the amino terminal end (residues 
1-51) and a Src homology region 3 (SH3) domain [18] at the 
C-terminal end (residues 197-261) of the protein. In addition, 
the primary sequence of Lasp-1 that we deduced contained two 
probable tyrosine phosphorylation sites (Y52 and Y]52)- It has 
previously been reported that Src homology region 2 (SH2) 
domains [19,20] bind to phospho-tyrosine [21], and that short 
tripeptides, following the phospho-tyrosine residue, are respon- 
sible for the specificity of this interaction [22]. Interestingly, the 
tripeptides following the Lasp-1 putative phospho-tyrosine res- 
idues (Y52 and YI52) are compatible with those already de- 
scribed for SH2 binding motifs [22], suggesting that Lasp-I 
could interact with SH2 containing proteins. 
3.4. Lasp-1 LIM domain 
The LIM domain is an arrangment of eight cysteine and 
histidine residues (C-X2-C-X16123-H-X2-C-X2-C -X2-C-X16/21-C- 
Xz/3-C/D/H) and is found in a number of invertebrate and 
vertebrate proteins [17]. The LIM domain defines a zinc bind- 
ing structure that is properly folded in presence of Zn. The LIM 
generic name was drawn from the names of the first three 
proteins identified containing such a domain (l_in-11, Isl-1 and 
mec-3). The family of LIM containing proteins is continously 
increasing and can be subdivided into distinct groups [17]. One 
group designated LIM-HD, includes proteins having two LIM 
domains associated with a homeodomain (lin-11, Isl-1, mec-3). 
Another group designated LIM-only, includes proteins exhibit- 
ing one (CRIP), two (CRP, TSF3, RBTN1, RBTN2, RBTN3) 
or three (zyxin) LIM domains. Recently, a new group desig- 
nated LIM-k has been described; it includes proteins having 
two LIM domains associated with a kinase domain [23]. 
Sequence alignment of the Lasp-1 LIM domain showed a 
high homology (66% identity and 80% similarity) with that of 
the putative C. elegans YLZ4 protein (Accession P34417), al- 
though the overall protein homology was low (36% identity and 
55% similarity). The LIM domain of YLZ4 does not perfectly 
fit the LIM consensus, ince the first two cysteines are spaced 
by four instead of two residues, leading to a gap in the align- 
ment (Fig. 3A). Among other LIM containing proteins, besides 
the conserved LIM residues, additional homologies were found 
in the human cysteine-rich intestinal protein CRIP [24], the rat 
cysteine-rich protein CRP [25] and the sun flower transcription 
factor SF3 (TSF3) [26]. The physiological function of these 
proteins is not yet known, although arole for CRIP in intestinal 
zinc absorption has been suggested. Moreover, CRP was iden- 
tified as a binding partner for another LIM protein, the zyxin, 
presumed to have regulatory or signalling functions in focal 
adhesion plaques [27-29]. The interaction between these two 
proteins is mediated through specific LIM domain interactions 
[30]. Thus, the LIM domain can be considered as a protein/ 
protein binding modular interface, similar to the SH2 and SH3 
domains [30]. 
Fig. 2. Nucleotide and deduced amino acid sequences of human Lasp-1. (A) Nucleotides and amino acids are numbered on the left and right, 
respectively. The residues involved in the LIM domain are underlined and printed in bold characters and those of the SH3 domain in bold characters 
(e) indicates tyrosine residues that are possibly phosphorylated. An asterisk denotes the termination codon. The signal for polyadenylation is 
underlined. (B) The Lasp-1 cDNA is schematically represented (0-3848 bp), the shaded box indicates the protein-coding region. The relative positions 
of the different EST, homologous to Lasp-l, are indicated together with their corresponding length and accession umbers. 
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1 GC CTCCCG~CAG~TCGCCTCGGGGAACAGGACGCGCGTGAGCTCAGGCGT~CCCGCCCCAGCT~TTCTCGGAACCATGAACCCCAAC` TG~GCCCGGTGCG 
M N P N ~ A R C G 9 
101 GCAAGATCGTGTATCCCACGGAGAAGGTGAACTGTCTGGATAAGTTCTGG•ATAAAGCATGCTTCCATTGCGAGACCTGCAAGATGACACTGAACATGAA 
K I V Y  P T E K V N  C L DK FWI~ K A C  F H~ E TC K M T LN M K 42 
201 GAACTACAAGGGCTACGAGAAGAAGCC CTACTGCAACGCACACTACC CAAGCAGTCCTTCACCATGGTGGCGGACACCC CGGAAAACCTTCGCCTCAAG 
N Y K G Y E K K  P Y ~ N A H Y P K Q S  F T M V A D T  P E N L R L K  75 
301 C/~CAGAGT GAGC T C CAGAGT CAGGT G C ;CTACA~G GAGGAGTT TGAG.~.G-~.C.~.GGGC.'~u~.GG TTTCAGC G TAG TGGCAGAC AC GC C C GAG C T C CAGA 
Q Q S E L Q S QV RY  K E E F E KN K G K G  F S V V A  D T P E L Q R I09  
401 GAATCAAGAAGACCCAGGAC CAGAT CAGTAATATAAAATAC CATGAGGAGTTTGAGAAGAGC CGCATGGGCCC TAGCGGGGGCGAGGGCATGGAGCCAGA 
I K K T  QD Q I SN I K Y H E  E F E K S  R M G  P S G G E  GM E P E 142 
501 GCGT CGGGATTCACAGGACGGCAGCAGCTACCGGCGGCC C CTGGAGCAGCAGCAGCCTCACCACATC C GACCAGTGCC CGGTTTACCAGCAGCCC AG 
RR D S Q DG S S Y RR P L E Q Q  Q PH H I PT  SA  P V Y  Q Q P Q 175 
601 CAGCAGCCGGTGGCCCAGTCCTATGGTG;CTAc1~GGAG~CTGCAGCCCCAGTCT~CATACAGCGCAGCGCC~CAGGTGGTC~CGGG-~GCC-GTACCGCG 
Q Q PV A Q S Y G GY K E P A A  PV S I Q R S A P  G G G G K R Y R A 2 0 9  
701 CGGTGTATGAC TACAGCGCCGCCGACGAGGACGAGGTCT CCTTC CAGGACGGGGACACCATCGTCAACGTACAGCAGATCGACGACGGCTGGATGTACGG 
V Y  D Y S A A  D E D Z V  S F Q D G  DT I V N V Q  Q I D D G W M  Y G 242 
801 GACGGTGGAGCGCAC CGGCGACACGGGGATGCTGCCGGACAACTACGTGGAGGACATCTGAAC CCGGAGCGCCC  CATCTGTCTTCAGCACATTC ACCG 
T V E R T G D T G M L P D N Y V E D I * 261 
901 CATCGCATCCGTCCTGGGCGTGAGCCGTCCATTCTTCAGTGTC TCTGTTTTTTAAAACCTGCGACAGCTTGTGATTCCTAC C CTCTTCCAGCTT CTTTT 
I001 GCCAACTGAAGCCTTCTTCTGCCACTTCTGCGGGCTC CCTC CTCTGGCAGGCTTCCCCCGTGATCGACTTCTTGGTTTTCTCTCTGGATGGAACGGGTAT 
1101 GGGCCTCTCTGGGGGAGGCAGGGCTGGAATGGGAGAC CTGTTGGC CTGTGGGC CTCACCTGCCCCTCTGTTCTCTC C CTCACATCCTC CTGCCCAGCTC 
1201 CT CACATAC CCACACATTCCAGGGCTGGGGTGAGCC TGACTGCCAGGACCC AGGTCA~C TCCCTACATTC CC CAGAGTGGGATCCACTTCTTGGTT 
1301 CCTGGGATGGCGA~CTCTGCCGCTGTGTAGGGACCAGTGGGATGGGCTCTACCTCTCTTTCTCAAAGA~GCTCTGCCCACCTGGGGTCTCTC 
1401 TCC CTACCTC CCTCCTCAGGGGCAACAACAGGAGAATGGGGTTCCTGCTGTGGGGCGAATTCATCC  C CCGCGCGTTCCTTCGCACACTGTGATTTT 
1501 GCCCTCCTGCCCACGCAGACCTGCAGCGGGCAAAGAGCTCCCGAGGAAGCACAGCTTGGGTCAGGTTCTTGCCTTTCTTAATTTTAGGGACAGCTACCGG 
1601 AAGGAGGGGAACAAC-GAGTTCTCTTC CGCAGCCC CTTTCCCCACGCC CACCCCCAGTCTCCAGGGACC CTTGCCTGCCTCCTAGGCTGGAAGC CATGGTC 
1701 CCGAAGTGTAGGGCAAGGGTGCCTCAGGACCTTTTGGTCTTCAGCCTCCCTCAGCCCCCAGGATCTGGGTTAGGTGGCCGCTCCTCCCTGCTCCTCATGG 
1801 GAAGATGTCTCAGAGCCTTCCATGACCTCCC TCCC CAGCCCAATGCCAAGTGGACTTGGAGCTGCACAAAGTCAGCAGGGAC CACTAAATCTCCAAGAC 
1901 CTGGTGTGCGGAGGCAGGAGCATGTATGTCTGCAGGTGTCTGACACGCAAGTGTGTGAGTGTGAGTGTGAGAGAT~C~TGTGTCTGTAGGTGT 
2001 CTCTGGGC CTGTGTGTGGGT~TTATGTGAGGGTATGAAGAGCTGTCTTCCCCTGAGAGTTTCCTCAGAACCCACAGTGAGA~AGGGCTC GGG 
2101 GCAGAGAAGTTCCTTAGGTTTTCTTTGGAATGAAATTCCTCCTTCCCCCCATCTCTGAGTGGAGGAAGCC CACCAATCTGCCCTTTGCAGTGTGTCAGGG 
2201 TGGAAGGTAAGAGGTTGGTGTGGAGTT~CTGCCATAGGGTCTGCAGCCTGCTGGGGCTAAGCGGTGGAGGAAGGCTCTGTCACTCCAGGCATATGTT 
2301 TCCCCATCTCTGTCT~CTACAGAATAGGGTGGCAGAAGTGTCACCCTGTGGGTGTCTCCCTCGGGGGCTCTTC CCCTAGACCTCCCCCTCACTTACA 
2401 TAAAGCTCCCTTGAAGCAAGAAAGAGGGTCCCAGGGCTGCAAAACTGGAAGCACAGCCTCGGGGATGGGGAGGGAAAGACGGTGCTATATC CAGTTCCTG 
2501 CTC TCTGCTCATGGGTGGCTGTGACAACCCTGGCCTCACTTGATTCATCTCTGGTTTTCTTC-CCAC CCTCTGGGAGTCC CATCCCATTTTCATCCTGAG 
2601 CCCAACCAGGC CTGCCATTGGCCTCTTGTCCCTTGGCACACTTGTACCCACAGGTGA~AGGACCTGAAGGTATTGGCCTGTTCAACAATCAGTCA 
2701 TCATGGGTGTTTTTGTCAA•TGCTTGTTAATTGATTTGGGGATGTTTGCCCCGAATGAGAGGTTGAC43AAAAGACTGTGGGTGGGGAGGCC CTGCCTGAC 
2801 CCATCCCTTTTCCTTTCTGGCCCCAGCCTAGGTGGAGGCAAGTGGAATATCTTATATTGGGCGATTTGGGGGCTCGGGGAGGCAGAGAATCTCTTGGGAG 
2901 TCTTGGGTGGCGCTGGTGCATTCTGTTTCCTCTTGATCTCAAAGCACAATGTGGATTTGGGGACCAAAGGTCAGGGACACATC C T AGAGGACCTGAG 
3001 TTTGGGAGAGTGGTGAGTGGAAGGGAGGAGCAGCAAGAAGCAGCCTGTTTTCACTCAGCTTAATTCTCCTTCCCAGATAAGGCAAGCCAGTCATGGAATC 
3101 TTGCTGCAGGCCCTCCCTCTACTCTTCCTGTCCTAAAAATA~CCGTTTTCTTACACACCCCCAGAGAGAGGAGGGACTGTCACACTGGTGCTGAGTG 
3201 ACCGGGGGCTGCT~GTCTGTTCTTTACCAAAAC CATC CATCCCTAGAAGAGCACAGAGCCCTGA~TGGGCTGGGCTGGGCTGAGCCCCTGGTC 
3301 TTCTCTACAGTTCACAGAGGTCTTTCAGCTCATTTAATCCCAGGAAAGAGGCATCAAAGCTAGAATGTGAATATAACTTTTGTGGGCCAATACTAAGAAT 
3401 AACAAGAAGCCCAGTGGTGAGGAAAGTGCGTTCTCCCAGCACTGCCTC TGTTTTCTCCCTCTCATGTC CCTCCAGGGAAAATGACTTTATTGCTTAATT 
3501 TCTGCCTTTCCCCCCTCACACATGCACTTTTGGGCCTTTTTTTATAGCTGGAAAAAACAAAATACCACCCTACAAACCTGTATTTAAAAAGAAACAGAAA 
3601 TGACCACGTGAAATTTGCCTCTGTC CAAACATTTCATCCGTGTGTATGTGTATGTGTGTGAGTGTGTGAAGCCGCCAGTTCATCTTTTTATATGGGGTTG 
3701 TTGTCTCATTTTGGTCTGTTTTGGTCCCCTCCCTCGTGGGCTTGTGCTCGGGATCAAACCTTTCTGGC CT TTATGATTCTGAACATTTGACTTGAAC A 
3801 CAAGTGAATCTTTCTCCTGGTGACTCAAATAAAAGTATAATTTTTA 
B 
F06105 
, 
0 
T34065 
Z45434 
T08349 
T34342 T51339 
T08601 T61881 
D12116 
T32161 T51225 
T32139 
M86141 T33826 
T60382 F04305 
T34158 
T24771 T32123 
T33692 
T10815 T15543 
I 
3848 bp I 500 bp I 
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A 
Lasp- i  H, sap iens  (1-51) 
YLZ4 C. e legans  (1-52) 
hCRIP  H. sap iens  (1-55) 
rCRP2 R, norveg lcus  (1-56) 
- (119-180) 
TSF3 H. annuus  (5-64) 
(104-162) 
Ident i ty  S imi la r i ty  
. .MNPNCAR. .CGKIVYPTE K%'NCLDKFWHKACFHCETCK MTLNMKNYKG YEKKPYCNAH Y ...... PKQ % % 
. . -SKKC- -E  De- -T - - -V -  ELK  . . . .  V -H  -QC-KCTVCG . . . . . . . . . . .  D -R- -CDPH -. ..... - -T 66 80 
. , .M-KCPK. .CN-E- -FA-  R -TS-G-D-H RPCLKC-KCG K- -TSGGHAE H-G- - -C -HP  CYVAMFG- -G  46 55 
. . -ASKCPK.  .CD-T- -FA-  - -SS -G-D-H -FCLKC-RCN K- -TpGGHAE HDG- -FC-KP  CYATLFG- -G  46 55 
TGEPNMCP- .  .CN-R- -FA-  - -TS -G-D-H RPCLRC-RCS K - -TPGGHAE HDGQ- -CH~P CYG ..... . .  44 56 
TGTTQKCT. .  VCE-T - -LVD -LVANQRV~IH- -C -RCHHCN S- -KLS-FNS FDGVV-CRHH FDQLFKRTGS 35 52 
EGTRDKCN. .  ACA . . . . .  I- R -KVDGTAYH R-C-KCCHGG C- ISPS- - IA  H-GRL-CKHH H IQLFKKKGN 40 54 
8 
Lasp-1 H. sap iens  (196-261) 
YLZ3 C. e legans  (134-200) 
EMSI H. sap iens  (486-550) 
ABPI  S. cerev is iae  (526-592) 
h / fy~ H. sap iens  (76-141) 
h/src  H. sap iens  (78-144) 
h / f rg  H. sap iens  (71-135) 
h /yes  H. sap iens  (85-152) 
Ident i ty  S imi la r i ty  
RSAP GGGGKRYRAV YDySAADEDE VSFQDGDTIV  NVQQIDDGWMYGTVERTGDT GMLPDNI~/ED I* % % 
I -PT -KA-FAVK- I  - - -A - - -K - -  I - - LE - - I - -  -CEK . . . . . .  T - - -Q- -LQW .. . .  A - - -QP  HK 57 74 
DEYE NDL-YTAV-L  - - -Q- -GD- -  I - -DPDDI -T  - IEM . . . . .  W R-VCK. . -RY  -LF -A  . . . .  L RQ* 44 65 
PEKK PKENPWAT-E  - - -D - -EDN-  LT -VEN-K- I  - IEFV- -D-W L -EL -KD-SK  . . . .  S - - -SL  GN* 33 60 
-TRG -T -VTLFV-L  - - -E -RT- -D  L - -HK-EKFQ ILNSSEGD-W EARSLT- -E -  -Y I -S - - -AP  VD 35 56 
AGPL  A - -VTTFV-L  - - -ESRT-TD L - -KK-ERLQ I -NNTEGD-WLAHSLS- -Q-  -Y I -S - - -AP  SD 33 55 
-GVS - I -VTLF I -L  - - -E -RT- -D  LT -TK-EKFH I IATNTEGD-WEARSLSS-K-  -C I -S - - -AP  VD 32 52 
PAGL T - -VT IFV-L  - - -E -RTTED L - -KK-ERFQ I INNTEGD-WEARSIA- -KN -Y I -S - - -AP  AD 30 50 
Fig. 3, Comparison of Lasp-1 LIM and SH3 domains with those from various proteins. (A) The consensus LIM domain residues are in bold, identical 
residues are dashed, (.) indicates gap in the alignment. (B) SH3 conserved orsemi-conserved r sidues in more than half of the aligned sequences are 
in bold. Identical residues are dashed. ( ) indicates gaps in the alignment. 
3.5. Lasp-1 SH3 domain 
SH3 is a small protein domain of 60 amino acids, first iden- 
tified as a conserved sequence inthe non-catalytic amino termi- 
nal part of the src protein tyrosine kinase [19,20]. The function 
of SH3 domain remains unclear. A number of proteins involved 
in the tyrosine kinase signal transduction pathway contain SH3 
domains [21]. This domain is also found in proteins of unrelated 
function, such as proteins associated with the cytoskeleton [18]. 
SH3 containing proteins are usually located close to the plasmic 
membrane, suggesting that the SH3 domain may be implicated 
in localizing them to this cell compartment. Accordingly, the 
involvement ofthe SH3 domain in the targetting of the adaptor 
molecule Grb2 has been demonstrated [31]. Hints concerning 
the function were obtained from the crystallographic resolution 
of different SH3 domains, showing that, in spite of limited 
sequence similarity, the overall secondary and tertiary struc- 
tures are well conserved revealing a domain that is indepen- 
dantly folded in the protein [32]. The SH3 domain has been 
reported to be able to interact with proteins through specific 
proline-rich SH3 binding regions [33]. 
Sequence alignment revealed homology of the Lasp-1 C- 
terminal part with several SH3 domains (Fig. 3B), including 
that of EMS1 [34], a human homolog of the src tyrosine kinase 
substrate cortactin [35]. The strongest conservation f this SH3 
domain (57% identity and 74% similarity) was found with the 
putative YLZ3 protein of C. elegans (Accession P34416), al- 
though the overall protein homology is low (23% identity and 
40% similarity). Interestingly, on the F42H10.3 cosmid which 
contains part of the C. elegans chromosome IlI [36], the gene 
encoding YLZ3 lies next to the gene encoding YLZ4 which was 
previously shown to contain the LIM domain most homolo- 
gous with that of Lasp-1 (Fig. 3A). This may reflect processes 
of evolution that can lead to the association i the same protein 
of two functional domains, originally encoded by two consecu- 
tive genes. 
In conclusion, Lasp-1 carries a LIM and a SH3 domain, 
which represent modular structures present in various proteins, 
often in association with other functional domains. Thus, two 
LIM protein subfamilies have already been shown to contain 
a L1M domain associated with either a homeo or a kinase 
domain [17]. In addition, SH3 domains are often found in 
association with SH2, pleckstrin homology (PH) and kinase 
domains [37-39]. To date, Lasp-1, which is the first protein 
containing LIM and SH3 domains, defines a new LIM protein 
subfamily. These domains are known to be involved in protein/ 
protein interactions important for different cellular processes, 
such as transcription, cell transformation a d cell signalling 
[17,21,32]. The ubiquitous expression of Lasp-1 in human adult 
tissues uggests a basic cellular function for this protein. Lasp- 1 
is overexpressed in 8% of breast carcinomas. Thus, the Lasp-1 
protein which may be involved as an adaptor molecule in a 
signalling pathway, may contribute to cell transformation a d/ 
or tumor progression. 
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